LogicBio Therapeutics (NASDAQ:LOGC) and DBV TECHNOLOGIE/S (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for LogicBio Therapeutics and DBV TECHNOLOGIE/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LogicBio Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| DBV TECHNOLOGIE/S | 0 | 1 | 5 | 0 | 2.83 |
LogicBio Therapeutics currently has a consensus target price of $23.00, indicating a potential upside of 211.65%. DBV TECHNOLOGIE/S has a consensus target price of $16.60, indicating a potential upside of 43.72%. Given LogicBio Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe LogicBio Therapeutics is more favorable than DBV TECHNOLOGIE/S.
Valuation & Earnings
This table compares LogicBio Therapeutics and DBV TECHNOLOGIE/S’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LogicBio Therapeutics | N/A | N/A | -$17.62 million | ($3.04) | -2.43 |
| DBV TECHNOLOGIE/S | $17.17 million | 61.40 | -$196.14 million | ($3.39) | -3.41 |
LogicBio Therapeutics has higher earnings, but lower revenue than DBV TECHNOLOGIE/S. DBV TECHNOLOGIE/S is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares LogicBio Therapeutics and DBV TECHNOLOGIE/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LogicBio Therapeutics | N/A | -52.99% | -48.49% |
| DBV TECHNOLOGIE/S | N/A | N/A | N/A |
Risk & Volatility
LogicBio Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, DBV TECHNOLOGIE/S has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Insider & Institutional Ownership
55.9% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 32.9% of DBV TECHNOLOGIE/S shares are owned by institutional investors. 49.9% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 15.3% of DBV TECHNOLOGIE/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
LogicBio Therapeutics beats DBV TECHNOLOGIE/S on 7 of the 12 factors compared between the two stocks.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with .